A Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Participants With Sjögren's
Active, not recruiting · Phase 2 · NCT06928142
Conditions: Sjogren Disease
At a glance
- Research payments reported, 2025
- $603,863
- U.S. investigators named
- 17
- Sites paid
- 17
- Planned or actual enrollment
- 83
About the trial
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Tested
- Sibeprenlimab (biological), Placebo (other)
- Dates
- Started 2025-04-23; completion 2027-06-04
- Results posted
- Not yet
This is a phase 2 study to evaluate the effects of sibeprenlimab 400 mg administered subcutaneously (SC) every 4 (Q4) weeks as an add-on to background treatment in participants with Sjögren's disease.
From ClinicalTrials.gov, last updated 2026-03-18. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Otsuka Pharmaceutical Development & Commercialization, Inc. reported $603,863 in research payments for this study in 2025 (31 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Natalia Chavez Stewart, M.D. Rheumatology · Corona, CA
- Dan T. La, MD Rheumatology · Tujunga, CA
- Mark Jaffe, M.D. Rheumatology · Hollywood, FL
- Edgard Janer, M.D., P.A. Specialist · Tampa, FL
- Robert W. Levin, M.D. Rheumatology · Clearwater, FL
- Saad Tariq, MD Rheumatology · Rockford, IL
- Saravanan Thiagarajan, M.D. Rheumatology · Baton Rouge, LA
- Athena S. Papas, DMD PHD Dentists (general) · Boston, MA
- Jane H. Box, MD Rheumatology · Charlotte, NC
- Leroy A. Pacheco, MD Rheumatology · Albuquerque, NM
- Sanford M. Wolfe, DO Rheumatology · Dayton, OH
- Tamar F. Brionez, MD Rheumatology · The Woodlands, TX
- Michelle Eisenberg, D.O. Rheumatology · Houston, TX
- Maryam Khawari, MD Rheumatology · Katy, TX
- Aman S. Kugasia, M.D, Rheumatology · Katy, TX
- Paul K. Pickrell, MD Rheumatology · Austin, TX
- Philip A. Waller, M.D. Rheumatology · Houston, TX
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Clinical Research of West Florida Inc $91,633
- Albuquerque Center for Rheumatology PC $72,650
- Vantage Clinical Trials Inc $56,120
- $54,029
- Biovin Enterprises LLC $48,390
- Accurate Clinical Research Inc $36,250
- Arh Research LLC $29,138
- Djl Clinical Research PLLC $27,000
- Gnp Consultants LLC $25,588
- Premier Clinical Research LLC $23,714
- Clinical Research of West Florida $23,250
- Ochsner Medical Center Acute, LA $22,300
- Tekton Research LLC $20,769
- Pharmaseek LLC $20,150
- Prolato Research LLC $19,350
- Orthomidwest PLLC $12,800
- Accurate Clinical Management LLC $12,700
- Trustees of Tufts College $8,031
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.